A selected list of oncolytic viruses in clinical trials
Click on the company or institution name for more information on the clinical trials
|Virus||Selective targeting method||Indications||Human trial status||Companies/Institutions (candidate)|
|Adenovirus||E1B deletion restricts replication to cells with abberant mRNA transport||Head and neck tumors||Phase III||Sunway Biotech of China (H101)|
|Head and neck tumors||Phase III (canceled)||Onyx (O15)|
|Coxsackie virus||Targets DAF/intercellular adhesion molecule 1, which is overexpressed in cancer||Stage IV melanoma||Phase I||Viralytics (A21)|
|Herpes simplex virus 1||ICP34.5 deletion restricts replication to cells with active replication||Melanoma||Phase II||BioVex (OncoVEXGM-CSF)|
|Glioma, astrocytoma, glioblastoma||Phase I/II||MediGene (G207, NV1020)|
|Glioma, melanoma, squamous cell carcinoma of the head and neck||Phase I/II||Crusade Laboratories (HSV1716)|
|Measles virus||Engineered to target CD46 on tumor cells||Brain and central nervous system tumors||Phase I||Mayo Clinic (MV-CEA)|
|Newcastle disease virus||Naturally unable to...|
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?